Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020
Debt
Debt-to-Equity RatioN/A
Current Ratio3.80
Quick Ratio3.80
Price-To-Earnings
Trailing P/E Ratio-3.78
Forward P/E Ratio-5.14
P/E GrowthN/A
Sales & Book Value
Annual Sales$17.55 million
Price / Sales16.05
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book3.95
Profitability
EPS (Most Recent Fiscal Year)($3.22)
Net Income$-38,700,000.00
Net Margins-263.80%
Return on Equity-124.32%
Return on Assets-36.28%
Miscellaneous
Employees78
Outstanding Shares23,150,000
Market Cap$294.75 million
Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions
What is Mersana Therapeutics' stock symbol?
Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."
How were Mersana Therapeutics' earnings last quarter?
Mersana Therapeutics Inc (NASDAQ:MRSN) released its quarterly earnings data on Wednesday, August, 15th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.58) by $0.04. The business earned $4.19 million during the quarter, compared to analysts' expectations of $3.74 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%. View Mersana Therapeutics' Earnings History.
When is Mersana Therapeutics' next earnings date?
What price target have analysts set for MRSN?
5 Wall Street analysts have issued 12-month target prices for Mersana Therapeutics' stock. Their forecasts range from $16.00 to $61.00. On average, they anticipate Mersana Therapeutics' share price to reach $30.00 in the next year. This suggests a possible upside of 146.5% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.
What is the consensus analysts' recommendation for Mersana Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.
Who are some of Mersana Therapeutics' key competitors?
Some companies that are related to Mersana Therapeutics include Athenex (ATNX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), Zai Lab (ZLAB), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Apellis Pharmaceuticals (APLS), Radius Health (RDUS), Assembly Biosciences (ASMB), TG Therapeutics Inc common stock (TGTX) and Revance Therapeutics (RVNC).
Who are Mersana Therapeutics' key executives?
Mersana Therapeutics' management team includes the folowing people:
- Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
- Mr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 54)
- Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
- Mr. Mikhail Papisov Ph.D., Co-Founder
- Mr. Wayne Foster, VP of Fin.
When did Mersana Therapeutics IPO?
(MRSN) raised $75 million in an IPO on Wednesday, June 28th 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Has Mersana Therapeutics been receiving favorable news coverage?
Media headlines about MRSN stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mersana Therapeutics earned a daily sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the company an impact score of 46.48 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Mersana Therapeutics.
Who are Mersana Therapeutics' major shareholders?
Mersana Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.39%), Point72 Asset Management L.P. (0.62%), Millennium Management LLC (0.54%), American Century Companies Inc. (0.19%), Bank of New York Mellon Corp (0.14%) and Schwab Charles Investment Management Inc. (0.11%). Company insiders that own Mersana Therapeutics stock include M James Barrett and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.
Which major investors are selling Mersana Therapeutics stock?
Which major investors are buying Mersana Therapeutics stock?
MRSN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, American Century Companies Inc., Rhumbline Advisers, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Mersana Therapeutics.
How do I buy shares of Mersana Therapeutics?
Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mersana Therapeutics' stock price today?
One share of MRSN stock can currently be purchased for approximately $12.17.
How big of a company is Mersana Therapeutics?
Mersana Therapeutics has a market capitalization of $294.75 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.
How can I contact Mersana Therapeutics?
Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]
MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
